Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of an H5N1 VLP [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety, reactogenicity, and immunogenicity results for Novavax's H5N1 virus-like particle vaccine evaluated in Phase 1/2 for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• H5N1 Virus-Like Particle Vaccine (virus-like particle vaccine against H5N1 influenza)

Snippet

Sponsor: Novavax | Conditions: Pandemic Influenza | Phase 1, Phase 2 | Status: COMPLETED